Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
35 SEK | -1.41% | -6.91% | -32.69% |
May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Sales 2024 * | 154M 14.54M | Sales 2025 * | 189M 17.93M | Capitalization | 2.32B 220M |
---|---|---|---|---|---|
Net income 2024 * | 40M 3.79M | Net income 2025 * | 49M 4.64M | EV / Sales 2024 * | 14.4 x |
Net cash position 2024 * | 108M 10.25M | Net cash position 2025 * | 128M 12.11M | EV / Sales 2025 * | 11.6 x |
P/E ratio 2024 * |
57.4
x | P/E ratio 2025 * |
48.4
x | Employees | 36 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | -1.41% | ||
1 week | -6.91% | ||
Current month | -8.50% | ||
1 month | +16.28% | ||
3 months | -11.62% | ||
6 months | -28.93% | ||
Current year | -32.69% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 35 | -1.41% | 9 152 |
24-06-07 | 35.5 | -2.61% | 49,936 |
24-06-05 | 36.45 | -6.90% | 48,491 |
24-06-04 | 39.15 | +4.12% | 47,611 |
24-06-03 | 37.6 | -1.70% | 44,445 |
Delayed Quote Nasdaq Stockholm, June 10, 2024 at 04:09 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.69% | 220M | |
-7.46% | 11.98B | |
-5.68% | 8B | |
+7.52% | 5.85B | |
+28.87% | 5.54B | |
-15.84% | 3.84B | |
+10.70% | 2.66B | |
-60.92% | 2.62B | |
-8.06% | 2.33B | |
-8.85% | 1.78B |
- Stock Market
- Equities
- GENO Stock